A Two-Week Neurotoxin Is Not a Trial Run

By Dr. Iryna Lazuk, MD — Physician-led perspective from Lazuk Esthetics in Alpharetta, Georgia.
Direct answer: A short-duration neurotoxin may be useful for an adult who wants a rapid-onset, temporary glabellar-line treatment and accepts that the effect may return to baseline in roughly two to three weeks. It is not a risk-free “test Botox.” TrenibotulinumtoxinE is authorized in the European Union as Boey, but it was not FDA approved in the United States after an April 2026 complete response letter.
The newest injectable proposition is not longer. It is deliberately brief—and that changes the treatment math more than it changes the medical obligation.
What is actually new about toxin E?
Most aesthetic neurotoxins use botulinum toxin type A and are planned around effects that last for months. Boey contains trenibotulinumtoxinE, a different serotype with onset reported as early as eight hours and an effect that returns toward baseline in about two to three weeks.
The European authorization is for occasional treatment of moderate-to-severe glabellar lines with important psychological impact. It does not make the product a casual rehearsal for every facial area or every patient.
Is a shorter effect automatically easier?
Shorter duration can reduce the commitment to an unwanted cosmetic result, but it also compresses benefit, follow-up, and value into a brief window. An adverse event does not become trivial simply because the intended effect is short.
The choice is a tradeoff among speed, duration, indication, product availability, cost, repeat-treatment burden, and the patient’s tolerance for uncertainty. A familiar toxin A may be the more coherent plan; no treatment may be better still.
What would change my recommendation?
My recommendation changes with treatment naivety, anatomy, asymmetry, prior toxin response, neuromuscular or swallowing history, medications, event timing, approved indication, authentic sourcing, and whether a two-to-three-week result is actually worth the procedure burden.
I also weigh timing, recovery margin, reversibility, cumulative treatment burden, financial commitment, and whether observation would answer the question more safely.
When would I not recommend this?
I would not recommend importing or purchasing a non-U.S.-approved toxin, using a short-duration product as a party treatment, or assuming its units convert to another brand. I would also wait when the patient wants a durable result and would resent the maintenance math.
A pause is not indecision. It protects future options when the diagnosis, product, evidence, or follow-up plan is not yet strong enough.
How does this fit a North Atlanta plan?
For patients in Alpharetta and across North Atlanta, ultraviolet exposure, outdoor schedules, travel, event timing, seasonal dryness, and access to follow-up can change an otherwise reasonable plan.
Frequently asked questions
Is trenibotulinumtoxinE FDA approved in the United States?
No. AbbVie reported an FDA complete response letter in April 2026 related to manufacturing information; no U.S. approval should be assumed.
How long does Boey last?
EMA materials describe an early onset and short duration; company trial summaries report return toward baseline at about two to three weeks.
Is short duration safer?
Short duration changes commitment, not the need for screening, authentic product, qualified injection, consent, and an adverse-event plan.
Can toxin units be converted across brands?
No. Botulinum toxin potency units are product-specific and should not be casually converted.
Who might value a brief effect?
A carefully selected, treatment-hesitant adult may value reversibility of time, but availability, indication, burden, and medical risk still govern the decision.
Follow Dr. Lazuk
Dr. Iryna Lazuk is the physician co-founder of Lazuk Esthetics and Dr. Lazuk Cosmetics. I evaluate anatomy, skin behavior, health context, goals, evidence, timing, maintenance burden, and whether waiting is the better intervention.
Contact
Lazuk Esthetics | 4380 Kimball Bridge Rd, Alpharetta, GA 30022 | Concierge Service: (770) 744-3146
Medical disclaimer
This article is educational and does not diagnose a condition or establish treatment candidacy. Medication and procedure decisions require individualized evaluation by an appropriately qualified clinician.


Comments